Katsuyama, Hisayuki
Deutsches Diabetes-Zentrum e.V. · German Center for Diabetes Research · Heinrich Heine University Düsseldorf
3 papers on CoChatORCID 0000-0003-2871-8340
Most cited papers
- Verified
Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial
Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care
Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment
Cited by 360
- Verified
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial
Ueki, K., Sasako, T., Okazaki, Y., Kato, M., Okahata, S., Katsuyama, H., Haraguchi, M., Morita, A., Ohashi, K., Hara, K., et al. (2017) · The Lancet Diabetes & Endocrinology
Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 313
- Verified
Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways
Watanabe, T., Kubota, N., Ohsugi, M., Kubota, T., Takamoto, I., Iwabu, M., Awazawa, M., Katsuyama, H., Hasegawa, C., Tokuyama, K., et al. (2009) · Journal of Biological Chemistry
Adipokines, Inflammation, and Metabolic DiseasesPharmacology and Obesity Treatment
Cited by 53
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free